OPT-302

DRUG5 trials

Sponsors

Opthea Limited

Conditions

Diabetic Macular EdemaEye DiseasesMacular DegenerationNeovascular Age-related Macular DegenerationNeovascular Age-related Macular Degeneration (wet AMD)Neovascular age-related macular degeneration (wet AMD)Neovascularization, PathologicRetinal Degeneration

Phase 1

Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of OPT-302 With or Without Lucentis™ in Patients With Wet AMD

CompletedNCT02543229

Opthea LimitedEye Diseases, Macular Degeneration, Neovascularization, Pathologic +2

Start: 2015-07-31End: 2017-09-30Updated: 2017-11-06

A Dose Ranging Study of OPT-302 With Aflibercept for Persistent Diabetic Macular Edema

CompletedNCT03397264

Opthea LimitedDiabetic Macular Edema

Start: 2018-01-16End: 2020-06-11Updated: 2025-04-22

Phase 2

A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD

CompletedNCT03345082

Opthea LimitedNeovascular Age-related Macular Degeneration

Start: 2017-11-06End: 2019-05-14Updated: 2021-01-12

Phase 3

A Phase 3, Multicentre, Double-masked, Randomised Study to Evaluate the Efficacy and Safety of Intravitreal OPT-302 in Combination with Aflibercept, Compared with Aflibercept Alone, in Participants with Neovascular Age-related Macular Degeneration (nAMD)

CompletedCTIS2024-512880-30-00

Opthea LimitedNeovascular Age-related Macular Degeneration (wet AMD)

Start: 2021-08-27End: 2025-03-31Target: 475Updated: 2025-04-23

A Phase 3, Multicentre, Double-masked, Randomised Study to Evaluate the Efficacy and Safety of Intravitreal OPT-302 in Combination with Ranibizumab, Compared with Ranibizumab Alone, in Participants with Neovascular Age-related Macular Degeneration (nAMD)

CompletedCTIS2024-512879-13-00

Opthea LimitedNeovascular age-related macular degeneration (wet AMD)

Start: 2021-09-23End: 2025-03-31Target: 298Updated: 2025-04-23

Related Papers

A Randomized Controlled Trial of OPT-302, a VEGF-C/D Inhibitor for Neovascular Age-Related Macular Degeneration.

2023-02-0633 citations